Arcutis Biotherapeutics
Public medical-dermatology company whose Zoryve franchise has become relevant to PHD through the recent pediatric label expansion wave.
Westlake Village, California
2016
NASDAQ: ARQT
Commercial Insurance
What They Do
Arcutis Biotherapeutics develops and commercializes dermatology treatments focused on immune-mediated skin diseases. Its commercial anchor is the Zoryve (roflumilast) franchise, spanning cream and foam formulations across plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. The company matters to PHD because it is not treating pediatrics as an off-label afterthought: it has kept expanding the same franchise into younger populations through formal FDA work, including children as young as 2 in plaque psoriasis.
Competitive Position
Arcutis is not a maternal-pediatric startup peer. Its relevance is strategic: it is competing against entrenched dermatology standards such as topical steroids and other non-steroidal branded agents like Dermavant's Vtama, while also sitting adjacent to larger systemic players such as Sanofi and Regeneron's Dupixent in atopic dermatitis. Arcutis differentiates by pushing once-daily, steroid-free topical options across multiple inflammatory skin conditions and then extending those labels into younger pediatric cohorts.
Funding Rounds
No funding rounds on record for this company.